1152475-50-7

Basic information

• Product Name: 2-Chloro-7-iodo-5H-pyrrolo[3,2-d]pyrimidine
• Synonyms: 2-Chloro-7-iodo-5H-pyrrolo[3,2-d]pyrimidine
• CAS NO: 1152475-50-7
• Molecular Formula: C₆H₃ClIN₃
• Molecular Weight: 279.46559
• Product Categories: Heterocycle-Pyrimidine series
• Mol File: 1152475-50-7.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Density: 2.284
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: 2-Chloro-7-iodo-5H-pyrrolo[3,2-d]pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloro-7-iodo-5H-pyrrolo[3,2-d]pyrimidine(1152475-50-7)
• EPA Substance Registry System: 2-Chloro-7-iodo-5H-pyrrolo[3,2-d]pyrimidine(1152475-50-7)

Safety Data

• Hazardous Substances Data: 1152475-50-7(Hazardous Substances Data)

Usage

Description

2-Chloro-7-iodo-5H-pyrrolo[3,2-d]pyrimidine is a heterocyclic chemical compound characterized by a molecular formula of C7H3ClIN2. It features a distinctive fused ring system comprising a pyrrole and a pyrimidine, which endows it with unique structural and reactivity properties. 2-Chloro-7-iodo-5H-pyrrolo[3,2-d]pyrimidine is recognized for its potential in the creation of novel molecules with significant biological and therapeutic applications.

Uses

Used in Pharmaceutical Industry:
2-Chloro-7-iodo-5H-pyrrolo[3,2-d]pyrimidine serves as a crucial intermediate in the synthesis of a variety of pharmaceutical drugs and agrochemicals. Its unique structure allows for the development of new compounds with potential therapeutic effects, contributing to the advancement of medicinal chemistry.
Used in Organic Synthesis:
As a building block in organic synthesis, 2-Chloro-7-iodo-5H-pyrrolo[3,2-d]pyrimidine is utilized for the construction of complex organic molecules. Its reactivity and structural features make it a valuable component in the synthesis of diverse organic compounds.
Used in Chemical Research:
In the realm of chemical research, 2-Chloro-7-iodo-5H-pyrrolo[3,2-d]pyrimidine acts as a reagent, facilitating the exploration of new chemical reactions and the discovery of novel chemical properties. Its application in research supports the expansion of scientific knowledge and the development of innovative chemical methodologies.

Upstream product

• 63200-54-4 2,4-dichloro-5H-pyrrolo[3,2-d]pyrimidine 
• 1119280-66-8 2-chloro-5H-pyrrolo[3,2-d]pyrimidine? 

Downstream Products

• 1152475-62-1 2-chloro-7-iodo-5-methyl-5H-pyrrolo[3,2-d]pyrimidine 

Relevant articles and documents

Discovery of 3-Cyano- N-(3-(1-isobutyrylpiperidin-4-yl)-1-methyl-4-(trifluoromethyl)-1 H-pyrrolo[2,3- b]pyridin-5-yl)benzamide: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor C2 Inverse Agonist

The nuclear hormone receptor retinoic acid receptor-related orphan C2 (RORC2, also known as RORγt) is a promising target for the treatment of autoimmune diseases. A small molecule, inverse agonist of the receptor is anticipated to reduce production of IL-17, a key proinflammatory cytokine. Through a high-throughput screening approach, we identified a molecule displaying promising binding affinity for RORC2, inhibition of IL-17 production in Th17 cells, and selectivity against the related RORA and RORB receptor isoforms. Lead optimization to improve the potency and metabolic stability of this hit focused on two key design strategies, namely, iterative optimization driven by increasing lipophilic efficiency and structure-guided conformational restriction to achieve optimal ground state energetics and maximize receptor residence time. This approach successfully identified 3-cyano-N-(3-(1-isobutyrylpiperidin-4-yl)-1-methyl-4-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzamide as a potent and selective RORC2 inverse agonist, demonstrating good metabolic stability, oral bioavailability, and the ability to reduce IL-17 levels and skin inflammation in a preclinical in vivo animal model upon oral administration.

N-CONTAINING HETEROCYCLIC COMPOUNDS

The present invention relates to N-containing heterocyclic compounds that are inhibitors of protein kinases including JAK kinases. In particular, the compounds are selective for JAK1, JAK2, JAK3 or TYK2 kinases and combinations thereof such as JAK1 and JAK2. The kinase inhibitors can be used in the treatment of kinase associated diseases such as immunological and inflammatory diseases including organ transplants; hyperproliferative diseases including cancer and myeloproliferative diseases; viral diseases; metabolic diseases; and vascular diseases.